The stock market has recovered some of its losses over the past month, rising by nearly 11% in this period. Some companies are tagging along, including BioXcel Therapeutics (NASDAQ: BTAI) , a small-cap biotech stock. BioXcel remains deep in the red for the year, but ongoing developments have helped fuel the company's recent run. And at a market capitalization of $430 million, its shares might be worth buying if there is more fuel left in its growth tank. Is this drugmaker worth investing in today?
For further details see:
Is This Soaring Growth Stock a Buy?